The ‘Translational Advances in Stem Cells for Diabetes Symposium’ aims to promote research interaction and collaboration at the intersection of diabetes and stem cell biology. Its scope covers stem cell-derived pancreatic islets for cell therapy, the understanding of diabetes pathogenesis using stem cells, the establishment of clinically relevant iPSCs, and precision medicine in diabetes.
I extend my warm welcome to all of you to the ‘Translational Advances in Stem Cells for Diabetes Symposium’, which is organized by the Steering Committee of Qatar Biomedical Research Institute (QBRI)-Harvard Stem Cell Institute (HSCI) Agreement. This year’s symposium will bring together leaders and trainees from cutting-edge fields of stem cells and diabetes.
The event aims to enable participants to exchange new ideas and develop innovative approaches on potential treatments of diabetes using stem cells.
I look forward to welcoming you!
Dr. Essam M. Abdelalim
Chair, Steering Committee of QBRI-HSCI Agreement
Scientist at Qatar Biomedical Research Institute, Hamad Bin Khalifa University (HBKU)
Joint Assistant Professor, College of Health and Life Sciences (CHLS), HBKU
On behalf of QBRI at HBKU, I am delighted to welcome you to the “Translational Advances in Stem Cells for Diabetes” symposium.
As part of Qatar’s National Vision 2030, we have been diligently working in alignment with the National Strategy to Prevent Diabetes in Qatar. Through our collaboration with (HSCI), we have been able to enhance QBRI’s capacity-building in stem cell technologies and perform stem cell research that increase our understanding of diabetes progression; paving the way to developing more effective treatments.
We are grateful to the QBRI-HSCI steering committee and symposium participants, as your engagement provides essential practical knowledge and strengthens the network and connections with stem cell experts.
We look forward to having you!
Dr. Omar Albagha
Acting Executive Director, Qatar Biomedical Research Institute, HBKU